Loading...
01/11 11:06
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed mixed sentiments. While there is optimism about long-term profitability and strategic partnerships, challenges such as delayed software growth and uncertain monetization timelines for new projects persist. The company's focus on discovery partnerships and reduced expenses are positive, but the lack of concrete guidance on key initiatives tempers enthusiasm. Given the market cap, the stock price is likely to remain stable in the short term, with a neutral prediction.
Total Revenue $54 million, a 54% increase from the third quarter of 2024, reflecting strong execution across the business.
Software Revenue $40.9 million, representing 28% year-over-year growth, driven by higher revenue from hosted contracts, on-premise renewals, and contribution revenue from the grant related to the predictive toxicology initiative.
Drug Discovery Revenue $13.5 million compared to $3.4 million in Q3 2024, reflecting continued successful execution across the expanded portfolio of collaborations.
Software Gross Margin 73% for both Q3 2025 and Q3 2024, indicating stable profitability in the software segment.
R&D Expenses $42.8 million in Q3 2025, a 16% decrease from $51 million in Q3 2024, primarily due to lower employee-related expenses and the shift of predictive toxicology expenses into software cost of goods sold.
Sales and Marketing Expense $9.5 million, an 8% decrease compared to Q3 2024, primarily due to lower employee-related expenses.
G&A Expenses $21.7 million, a 13% decrease compared to Q3 2024, primarily due to lower employee-related expenses.
Total Operating Expenses $74 million, a decrease of 14% compared to Q3 2024, driven by reductions in R&D, sales and marketing, and G&A expenses.
Total Other Income $13 million compared to $30 million in Q3 2024, due to mark-to-market changes in equity investments and currency fluctuations.
Net Loss $33 million or $0.45 per diluted share versus a net loss of $38 million or $0.52 per diluted share in Q3 2024, reflecting improved financial performance.
Cash and Equivalents $401 million as of September 30, 2025, indicating strong liquidity.
SGR-1505 (MALT1 inhibitor): Progress in Phase I package completion and clinical updates presented at the American Society of Hematology Conference. Demonstrated potential as a best-in-class treatment for relapsed/refractory B-cell malignancies.
SGR-3515 (Wee1/Myt1 co-inhibitor): Phase I dose escalation study ongoing for advanced solid tumors. Initial clinical data expected in H1 2026.
SGR-5573 (EGFR inhibitor): Pre-clinical data presented, showing potency against resistant EGFR variants and robust antitumor activity in brain metastases models.
SGR-6016 (NLRP3 inhibitor): Development candidate selected with potential best-in-class attributes, including brain penetrance and strong pre-clinical profile.
Software Revenue Growth: Updated guidance to 8%-13% for 2025 due to delays in pharma scale-up opportunities. Strong demand for computational solutions and AI integration in drug discovery.
Drug Discovery Revenue: Increased guidance to $49M-$52M for 2025, reflecting successful execution in collaborative programs.
Expense Management: Achieved $30M expense reduction in May, with additional savings expected in 2026. Total operating expenses decreased by 14% YoY in Q3 2025.
Platform Advancements: Released 2025-4 software update with enhancements for bifunctional degraders and predictive toxicology solutions. Expanded off-target support in the platform.
Shift in Clinical Development Strategy: Decision to not independently advance internal discovery programs into the clinic, focusing instead on strategic partnerships.
Focus on AI and Computational Drug Discovery: Positioned at the forefront of integrating computational physics and AI for molecular discovery, leveraging high-quality simulated data.
Software revenue growth guidance update: The company revised its software revenue growth guidance for 2025 to 8%-13% from 10%-15%, citing delays in pharma scale-up opportunities and a slowdown in pharma discussions due to industry pressures.
Macroeconomic pressures: Macroeconomic pressures have impacted the industry, leading to delays in customer engagements and affecting the timing of revenue realization.
Long sales cycle for scale-up opportunities: The relatively long sales cycle for pharma scale-up opportunities is causing delays in revenue growth.
Reduction in internal discovery programs: The company decided not to advance internal discovery programs into the clinic independently, which could limit its ability to capitalize on certain opportunities.
Expense reduction and operational efficiency: While the $30 million expense reduction improves operational efficiency, it also reflects a scaling back of certain activities, which may impact growth potential.
Dependence on strategic partnerships: The company is focusing on securing strategic partnerships for mid and late-stage development of its programs, which introduces dependency on external entities for success.
Industry pressures on biotech sector: The biotech sector is experiencing pressures, including challenges in capital markets, M&A, and new capital formation, which could impact the company's growth opportunities.
Regulatory and clinical trial risks: The company faces risks related to the timing and outcomes of clinical trials, as well as regulatory approvals for its drug candidates.
Software Revenue Growth Guidance for 2025: Updated to 8% to 13% from the previous 10% to 15%, reflecting current expectations regarding the timing of certain pharma scale-up opportunities.
Drug Discovery Revenue Guidance for 2025: Increased to $49 million to $52 million, slightly exceeding the prior expectation of $45 million to $50 million.
Software Gross Margin Guidance for 2025: Expected to be 73% to 75%, adjusted from the previous 74% to 75%, reflecting changes in software revenue expectations and a relatively fixed cost structure.
Expense Guidance for 2025: Operating expenses are expected to be lower than 2024, with cash used in operating activities significantly reduced compared to 2024.
Clinical Data for SGR-3515: Initial clinical data for the Wee1/Myt1 co-inhibitor is now expected in the first half of 2026, allowing more time for analysis and assembly of Phase I data.
Strategic Partnership for SGR-1505: Focus on securing a strategic partnership to ensure dedicated resources for mid and late-stage development of the MALT1 inhibitor.
NLRP3 Program Development: SGR-6016 selected as a development candidate, with potential best-in-class attributes, including brain penetrance and an encouraging pre-clinical profile.
Long-term Growth Outlook: Optimistic about long-term growth potential as industry pressures stabilize, with early signals of recovery in the biotech sector, including capital markets and M&A activities.
The selected topic was not discussed during the call.
The earnings call revealed mixed sentiments. While there is optimism about long-term profitability and strategic partnerships, challenges such as delayed software growth and uncertain monetization timelines for new projects persist. The company's focus on discovery partnerships and reduced expenses are positive, but the lack of concrete guidance on key initiatives tempers enthusiasm. Given the market cap, the stock price is likely to remain stable in the short term, with a neutral prediction.
The earnings call reveals mixed signals. Strong software revenue growth and a promising predictive toxicology initiative are positive. However, the cautious guidance and shift in clinical data timeline could dampen enthusiasm. The Q&A highlights demand consistency and constructive renewal discussions but lacks clarity on key metrics. The market cap suggests moderate reactions, leading to a neutral sentiment.
The earnings call shows strong financial performance with a 63% increase in total revenue and a significant increase in software and drug discovery revenues. Despite a net loss, the company has a strong cash position and reduced operating expenses. The Q&A section reveals confidence in their R&D and software offerings, with no immediate threats from competitors. The lack of a shareholder return plan is a minor downside. Overall, the positive revenue growth and strategic collaborations are likely to result in a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
